Combination therapies, including immune checkpoint inhibitors and tyrosine kinase (TK) or serine/threonine protein kinase B-Raf (BRAF) inhibitors, have shown significant potential for the treatment of advanced thyroid cancer (Iyer et al., 2018; Varricchi et al., 2019). Here, TKT is linked to thyroid cancer.